false000181428700018142872024-06-132024-06-130001814287us-gaap:CommonStockMember2024-06-132024-06-130001814287us-gaap:WarrantMember2024-06-132024-06-130001814287abl:FixedUnsecuredNotesMember2024-06-132024-06-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2024
Abacus Life, Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3940385-1210472
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
2101 Park Center Drive, Suite 200
Orlando, Florida 32835
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (800) 561-4148
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common stock, par value $0.0001 per shareABLThe NASDAQ Stock Market LLC
Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per shareABLLWThe NASDAQ Stock Market LLC
9.875% Fixed Rate Senior Notes due 2028ABLLLThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   



Item 7.01    Regulation FD Disclosure
On June 13, 2024, Abacus Life, Inc. (the “Company” or “Abacus”) issued a press release announcing the commencement of an underwritten offering of 10,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”), made pursuant to the Company’s Registration Statement on Form S-1, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) but has not yet become effective (such offering, the “Offering”).
A copy of the press release announcing the commencement of the Offering is furnished as Exhibit 99.1 hereto.
Item 9.01    Financial Statements and Exhibits.
(d)     The following exhibits are being filed herewith:
Exhibit No.Description
99.1
Forward Looking Statements
This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Abacus’ anticipated public offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements, such as the intended offering terms, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Abacus’ most recent annual report on Form 10-K, as amended, and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Abacus’ other filings with the SEC, including those contained in the preliminary prospectus and accompanying prospectus related to the public offering to be filed with the SEC. Any forward-looking statements represent Abacus’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Abacus explicitly disclaims any obligation to update any forward-looking statements, except as required by law.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ABACUS LIFE, INC.
Date: June 13, 2024By:/s/ Jay Jackson
Jay Jackson
Chief Executive Officer